Wexford Capital’s ADMA Biologics ADMA Stock Holding History

Wexford Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,605	Closed	-$36K	–	194
2020 Q4	$36K	Buy	+18,605	New	+$39.1K	0.01%	283

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Wexford Capital's ADMA Position: Q1 2021 in Review

Wexford Capital sold out of ADMA Biologics (ADMA) in Q1 2021, closing a stake of 18,605 shares — an estimated $36K sold.

Wexford Capital first reported a position in ADMA in Q4 2020 and held it in 1 quarter. The position peaked at $36K in Q4 2020. 105 funds tracked by Wall St. Rank hold ADMA as of Q1 2021.

Wexford Capital reported no remaining ADMA Biologics position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 18,605 ADMA Biologics shares in Q1 2021, an estimated $36K.
Wexford Capital first reported a position in ADMA Biologics in Q4 2020 and held it in 1 quarter.
Wexford Capital's ADMA Biologics position peaked at $36K in Q4 2020.
105 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.